Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex
TM Conner, VC Nikolian, PE Georgoff, MP Pai… - European Journal of …, 2018 - Elsevier
… design and validate a mechanistic model of VPA disposition in … drug-drug interactions (DDIs).
This study expands upon existing physiologically based pharmacokinetic (PBPK) models …
This study expands upon existing physiologically based pharmacokinetic (PBPK) models …
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
F Wu, G Krishna, S Surapaneni - Cancer Chemotherapy and …, 2020 - Springer
… PBPK model was then verified or refined based on additional clinical pharmacokinetic (PK)
and drug-drug interaction (DDI) observations for fedratinib. The verified PBPK models were …
and drug-drug interaction (DDI) observations for fedratinib. The verified PBPK models were …
Ribociclib drug‐drug interactions: Clinical evaluations and physiologically‐based pharmacokinetic modeling to guide drug labeling
… pharmacokinetic (PBPK) modeling is an increasingly used approach to predict drug-drug
interactions … be a victim and a perpetrator of drug-drug interactions (DDIs) involving the CYP3A …
interactions … be a victim and a perpetrator of drug-drug interactions (DDIs) involving the CYP3A …
Physiologically‐based pharmacokinetic modeling for the prediction of CYP2D6‐mediated gene–drug–drug interactions
… (CYP2D6)-mediated drug–drug interactions (DDIs) in … pharmacokinetic (PBPK) modeling.
Following the development of a new duloxetine model and optimization of a paroxetine model, …
Following the development of a new duloxetine model and optimization of a paroxetine model, …
Predicting drug–drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling
RKR Rajoli, P Curley, J Chiong, D Back… - The Journal of …, 2019 - academic.oup.com
… ; their interaction with rifampicin, a … drug–drug interactions (DDIs) between these LA
antiretroviral agents and rifampicin using physiologically based pharmacokinetic (PBPK) modeling…
antiretroviral agents and rifampicin using physiologically based pharmacokinetic (PBPK) modeling…
Prediction of drug-drug interactions with crizotinib as the CYP3A substrate using a physiologically based pharmacokinetic model
S Yamazaki, TR Johnson, BJ Smith - Drug Metabolism and Disposition, 2015 - ASPET
… a physiologically based pharmacokinetic (PBPK) model of … PBPK model from crizotinib
single-dose drug-drug interaction (… 3) apply the crizotinib PBPK model to predict crizotinib multiple-…
single-dose drug-drug interaction (… 3) apply the crizotinib PBPK model to predict crizotinib multiple-…
Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide
MVS Varma, RJ Scialis, J Lin, YA Bi, CJ Rotter… - The AAPS journal, 2014 - Springer
… , physiologically based pharmacokinetic models, assuming … pharmacokinetics and evaluate
drug interactions. Permeability-limited model successfully predicted glyburide interactions …
drug interactions. Permeability-limited model successfully predicted glyburide interactions …
Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in …
J Adiwidjaja, AV Boddy, AJ McLachlan - Frontiers in Pharmacology, 2020 - frontiersin.org
… based pharmacokinetic (PBPK) modeling approach to investigate optimal dosing regimens
and potential drug interactions with imatinib in the paediatric population. A PBPK model for …
and potential drug interactions with imatinib in the paediatric population. A PBPK model for …
Applications of physiologically based pharmacokinetic modeling of rivaroxaban—Renal and hepatic impairment and drug‐drug interaction potential
S Willmann, K Coboeken, S Kapsa… - The Journal of …, 2021 - Wiley Online Library
… could lead to drug-drug interactions. This physiologically based pharmacokinetic (PBPK)
study investigated the pharmacokinetic behavior of rivaroxaban in clinical situations where …
study investigated the pharmacokinetic behavior of rivaroxaban in clinical situations where …
Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling
C Costales, J Lin, E Kimoto, S Yamazaki… - CPT …, 2021 - Wiley Online Library
… Quantitative assessment of drug-drug interactions (DDIs) involving breast cancer resistance
… -based pharmacokinetic (PBPK) modeling to delineate the effects of inhibitor drugs on BCRP…
… -based pharmacokinetic (PBPK) modeling to delineate the effects of inhibitor drugs on BCRP…